Bayer has cautioned that its 2025 earnings will be affected by increased one-off charges related to ongoing litigation and restructuring expenses. The German life sciences company now expects special items to reduce its earnings before interest, tax, depreciation, and amortisation (EBITDA) by between EUR 3.5 billion and EUR 4.0 billion, higher than the earlier forecast of EUR 2.5 billion to EUR 3.5 billion.

Despite this revision, Bayer maintained its adjusted EBITDA guidance, excluding one-time charges and currency effects, at between EUR 9.7 billion and EUR 10.2 billion for the year. The higher expenses primarily stem from product liability cases, particularly those linked to its herbicide business, as well as costs from management buyouts and restructuring measures.

The company continues to focus on reducing debt, managing litigation exposure, and executing its strategic transformation to improve operational efficiency. Growth in its Crop Science segment and steady performance in Pharmaceuticals are expected to partially offset these challenges. However, the rising legal provisions and restructuring costs signal that 2025 will be a financially demanding year as Bayer navigates its turnaround efforts amid global market and regulatory pressures.